We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Artios Logo


Artios believe DNA damage response (DDR)-targeting therapies can play a significant role in the treatment of malignant disease, and they aim to take advantage of the full range of DDR therapeutic strategies to unlock new opportunities for patients. Artios' industry-leading expertise in this space has yielded a robust pipeline and platform with immense potential, which has led to collaborations with major pharma partners.